Stage (next event)
Phase 2 (Top-line Data)
Catalyst Info & Data Links
TITLE: IMU-838 (vidofludimus calcium) in COVID-19 - Phase 2 Top-line Data
ClinicalTrial.gov (NCT04379271): A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)
ClinicalTrial.gov (NCT04516915): IMU-838 and Oseltamivir in the Treatment of COVID-19 (IONIC)
WHAT IS THE CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Mechanism of Action
MECHANISM OF ACTION / RATIONALE
IMU-838 is a small molecule investigational drug (vidofludimus calcium) under development as an oral tablet formulation for the treatment of relapsing-remitting multiple sclerosis, or RRMS, inflammatory bowel disease, or IBD, and other chronic inflammatory and autoimmune diseases. The company is also investigating IMU-838 as a potential treatment option for coronavirus disease 2019, or COVID-19.
By inhibiting dihydroorotate dehydrogenase (DHODH), a key enzyme of pyrimidine de novo biosynthesis, metabolically activated T and B immune cells experience metabolic stress, and the release of Th1 and Th17 key cytokines including IL-17A, IL-17F and IFNg is inhibited, thereby reducing inflammation. In preclinical studies of vidofludimus, the active moiety and free acid form of IMU-838, apoptosis (or programmed cell death) was induced in activated T cells, which Immunic believes may also play a crucial role in the activity of the drug by further dampening the inflammatory response (Learn more).
Updated by HC
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post